Aveanna Healthcare Holdings Inc. (AVAH) Fundamental Analysis: Bull vs. Bear Case

AVAH

Aveanna Healthcare Holdings Inc.

Fundamental data last updated:September 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based pediatric therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

VALUATION

P/E

6.02 Market Cap ($M USD)

$1.60B

Forward P/E

8.80 PEG

-0.28

PRICE TO SALES

0.63 PRICE TO BOOK

6.55 EV / EBITDA

9.50 5-Year Average P/E

Free Cash Flow Yield

8.56%

DCF Value

$-9.56

Graham Number

$5.54

Price to FCF

11.68 EV to FCF

21.29 Earnings Yield

16.62%

FCF Yield

8.56%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.22

Next Year EPS Growth Estimate

$0.83

Next Year Revenue Growth Estimate

$2.92B

Return on Equity (ROE)

241.47%

FREE CASH FLOW

Operating Margin

11.48%

Debt-to-Equity

6.91 Piotroski F-Score

5 Altman Z-Score

1.58 Return on Invested Capital (ROIC)

17.74%

Current Ratio

1.47 Quick Ratio

1.47 Net Debt to EBITDA

4.29 Interest Coverage

2.18 Gross Profit margin

32.67%

FCF PER SHARE

$0.64

REVENUE PER SHARE

$11.75

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Aveanna Healthcare Holdings Inc., as its snapshot price traded below its DCF value, suggesting potential undervaluation. However, the Graham Number also indicates a lower intrinsic value, raising questions about its true worth. The Forward P/E of 9.04 and an Earnings Yield of 16.40% suggest a potentially attractive entry point for value investors, yet the Altman Z-score of 1.37 signals financial distress, hinting at underlying risks. The company’s financial health is a mixed bag, with impressive earnings yield overshadowed by structural vulnerabilities.

AI Exposure / Tech Reliance

Operating in the healthcare sector, Aveanna is well-positioned to leverage AI advancements in patient care and operational efficiency. The medical care facilities industry is ripe for tech integration, potentially enhancing service delivery and cost management. However, the company must strategically invest in tech to stay competitive and relevant.

The Bull Case

For the discerning value investor, Aveanna offers compelling reasons to buy. With a robust ROIC of 16.57%, the company demonstrates strong capital efficiency, translating into real-world pricing power. The FCF Yield of 8.58% and a Piotroski F-Score of 5 indicate solid financial health and operational efficiency. Its operating margin of 10.91% underscores effective cost management, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Despite some strengths, Aveanna faces significant structural risks. The Price/Book ratio of 7.05 and Price/Sales ratio of 0.60 suggest overvaluation relative to its book value and sales. The company's high Debt/Equity ratio of 6.91 raises alarms about its leverage and financial stability. Additionally, its proximity to the 52-week low indicates potential market skepticism about its future prospects.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$10.50

Institutional Ownership %

1-Year Beta

1.93 Insider Buying % (6 Mo)

Distance to 52-Week High

40.79%

Distance to 52-Week Low

49.11%

EARNINGS SURPRISE %

38.46%

50-DAY SMA

$6.77

200-DAY SMA

$8.01

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.